KOMIPHARM INTERNATIONAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,130 KRW | -0.48% |
|
-5.28% | -1.43% |
| 05-29 | Komipharm International Co., Ltd. announces an Equity Buyback for 481,927 shares. | CI |
| 05-29 | Komipharm International Co., Ltd. authorizes a Buyback Plan. | CI |
| Sales 2022 | 39.8B 28.82M 39.4M | Sales 2023 | 42.65B 30.88M 42.22M | Capitalization | 294B 213M 291M |
|---|---|---|---|---|---|
| Net income 2022 | -6.51B -4.72M -6.45M | Net income 2023 | -3.98B -2.88M -3.94M | EV / Sales 2022 | 11.9 x |
| Net Debt 2022 | 27.33B 19.78M 27.05M | Net Debt 2023 | 30.28B 21.92M 29.98M | EV / Sales 2023 | 7.6 x |
| P/E ratio 2022 |
-68.5
x | P/E ratio 2023 |
-73.5
x | Employees | 152 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.43% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.48% | ||
| 1 week | -5.28% | ||
| Current month | +0.36% | ||
| 1 month | -0.48% | ||
| 3 months | -11.85% | ||
| 6 months | -1.43% | ||
| Current year | -1.43% |
1 week
4 110.00
4 425.00
1 month
3 975.004 750.00
Current year
3 975.004 940.00
1 year
3 735.006 432.33
3 years
3 735.0014 763.47
5 years
3 735.0026 528.83
10 years
3 735.0047 510.56
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Cheol Moon
CEO | Chief Executive Officer | 64 | 93-04-25 |
Yong-Jin Yang
CEO | Chief Executive Officer | 70 | 88-06-26 |
Tae-Jin Han
AUD | Comptroller/Controller/Auditor | 68 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Jin Yang
CEO | Chief Executive Officer | 70 | 88-06-26 |
Seong-Cheol Moon
CEO | Chief Executive Officer | 64 | 93-04-25 |
Bong-Kyu Song
BRD | Director/Board Member | 63 | 17-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 4,130 | -0.48% | 59,667 |
| 24-06-27 | 4,150 | -0.84% | 60,543 |
| 24-06-26 | 4,185 | -0.71% | 50,726 |
| 24-06-25 | 4,215 | -3.55% | 99,759 |
| 24-06-24 | 4,370 | +0.23% | 63,848 |
End-of-day quote Korea S.E., June 27, 2024
More quotes
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.43% | 210M | |
| -12.16% | 79.1B | |
| -3.15% | 7.13B | |
| +21.25% | 3.58B | |
| -9.18% | 2.93B | |
| +16.05% | 1.69B | |
| -8.50% | 1.19B | |
| -33.05% | 1.11B | |
| -36.85% | 1.05B | |
| -27.92% | 939M |
- Stock Market
- Equities
- A041960 Stock
